PNB, Trent, TVS Motor, Shriram Finance, and Zydus Lifesciences will replace these five stocks in the Nifty Next 50 index, effective from September 29, 2023.
The USFDA has allowed Zydus to manufacture and market Estradiol Transdermal System USP in the U.S; the drug will be produced at the group’s facility in Moraiya, Ahmedabad.
India's healthcare firms spent $4.32 billion during January to June of 2022 on mergers and acquisitions, compared to $2.02 billion in the same period last year